Overview
MannKind Q3 2025 rev rises 17% yr/yr to $82.1 mln
Adjusted EPS for Q3 2025 increases 45% from last year
Company completes acquisition of scPharmaceuticals, boosting revenue growth
Outlook
Company expects FUROSCIX sNDA review decision by end of 2025
MannKind anticipates Afrezza pediatric sBLA decision by May 29, 2026
Company plans to enroll first patient in MNKD-201 IPF trial in Q1 2026
Result Drivers
ROYALTIES AND COLLABORATIONS - Revenue growth driven by increased royalties from Tyvaso DPI and higher collaborations and services revenue
AFREZZA REVENUE - Afrezza revenue increased due to higher price and demand, despite a decrease in V-Go revenue
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income | $7.98 mln | ||
Q3 Basic EPS | $0.03 | ||
Q3 Operating Income | $18.89 mln | ||
Q3 Pretax Profit | $7.78 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for MannKind Corp is $10.00, about 45.2% above its November 4 closing price of $5.48
The stock recently traded at 62 times the next 12-month earnings vs. a P/E of 17 three months ago
Press Release: ID:nGNX2dqwYK
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)